Estradiol Plus Olaparib for Breast Cancer (PHOEBE)

Determine the safety and recommended Phase II dose of olaparib in combination with 17b-estradiol in post-menopausal patients with advanced ER+/HER2- breast cancer.

Trial Details

NCT ID
NCT05900895
Phase
PHASE1
Sponsor
Mary D Chamberlin
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Olaparib
  • 17b-estradiol
Locations (sample)
  • Lebanon, New Hampshire, United States|43.64229,-72.25176

Key Eligibility Criteria

  • Post-menopausal women with ER+/HER2- breast cancer.
  • Metastatic or locoregional recurrence not amenable to treatment with curative intent.
  • Received ≥1 prior line of endocrine-based therapy in the advanced/metastatic setting.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →